LT3004090T - Cheminiai junginiai - Google Patents
Cheminiai junginiaiInfo
- Publication number
- LT3004090T LT3004090T LTEP14727036.7T LT14727036T LT3004090T LT 3004090 T LT3004090 T LT 3004090T LT 14727036 T LT14727036 T LT 14727036T LT 3004090 T LT3004090 T LT 3004090T
- Authority
- LT
- Lithuania
- Prior art keywords
- chemical compounds
- compounds
- chemical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361827951P | 2013-05-28 | 2013-05-28 | |
US201361915685P | 2013-12-13 | 2013-12-13 | |
PCT/GB2014/051607 WO2014191726A1 (fr) | 2013-05-28 | 2014-05-27 | Composés chimiques |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3004090T true LT3004090T (lt) | 2018-01-10 |
Family
ID=50841880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP14727036.7T LT3004090T (lt) | 2013-05-28 | 2014-05-27 | Cheminiai junginiai |
Country Status (35)
Country | Link |
---|---|
US (4) | US9155727B2 (fr) |
EP (2) | EP3004090B1 (fr) |
JP (1) | JP6286031B2 (fr) |
KR (1) | KR20160013198A (fr) |
CN (1) | CN105229004B (fr) |
AP (1) | AP2015008858A0 (fr) |
AU (1) | AU2014272856B2 (fr) |
BR (1) | BR112015029455A8 (fr) |
CA (1) | CA2911859A1 (fr) |
CL (1) | CL2015003491A1 (fr) |
CR (1) | CR20150629A (fr) |
CY (1) | CY1120474T1 (fr) |
DK (1) | DK3004090T3 (fr) |
DO (1) | DOP2015000274A (fr) |
ES (1) | ES2654161T3 (fr) |
HK (1) | HK1222859A1 (fr) |
HR (1) | HRP20171961T1 (fr) |
HU (1) | HUE035738T2 (fr) |
IL (1) | IL242559B (fr) |
LT (1) | LT3004090T (fr) |
ME (1) | ME02892B (fr) |
MX (1) | MX361538B (fr) |
NI (1) | NI201500167A (fr) |
PE (1) | PE20160874A1 (fr) |
PH (1) | PH12015502615B1 (fr) |
PL (1) | PL3004090T3 (fr) |
PT (1) | PT3004090T (fr) |
RS (1) | RS56678B1 (fr) |
RU (1) | RU2664109C2 (fr) |
SG (1) | SG11201509393VA (fr) |
SI (1) | SI3004090T1 (fr) |
TN (1) | TN2015000516A1 (fr) |
TW (1) | TWI653235B (fr) |
UY (1) | UY35590A (fr) |
WO (1) | WO2014191726A1 (fr) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096744A1 (fr) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Agents antiviraux de l'hépatite b |
JP2015533782A (ja) | 2012-08-28 | 2015-11-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 |
HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
PT2997019T (pt) | 2013-05-17 | 2018-11-21 | Janssen Sciences Ireland Uc | Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b |
PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
ES2655518T3 (es) | 2013-10-23 | 2018-02-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
ES2792848T3 (es) | 2014-02-05 | 2020-11-12 | Novira Therapeutics Inc | Politerapia para el tratamiento de infecciones por VHB |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
WO2016097072A1 (fr) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Modulateurs des récepteurs des oestrogènes tétrahydro-pyrido[3,4-b]indole et utilisations associées |
WO2016146591A1 (fr) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Traitement de combinaison |
CN107847762A (zh) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
EP3312184A4 (fr) * | 2015-06-16 | 2019-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | Dérivé pipéridine et son procédé de préparation et utilisation pharmaceutique associée |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2017024318A1 (fr) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Dégradation de protéines ciblées destinée à atténuer une thérapie par transfert adoptif de cellules t associée des réponses inflammatoires indésirables |
AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
AU2016331065B2 (en) | 2015-10-01 | 2021-04-29 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs |
KR102099159B1 (ko) * | 2015-11-12 | 2020-04-10 | 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 | 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법 |
EP3386968A4 (fr) | 2015-12-09 | 2019-09-25 | The Board of Trustees of the University of Illinois | Composés régulateurs à la baisse des récepteurs des strogènes sélectifs à base de benzothiophène |
US10398689B2 (en) | 2015-12-22 | 2019-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
EP3411034B1 (fr) * | 2016-02-05 | 2020-11-25 | Inventisbio Inc. | Agents de dégradation sélectifs des récepteurs des strogènes et leurs utilisations |
CN113717170A (zh) | 2016-04-01 | 2021-11-30 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂 |
EP3848026A1 (fr) | 2016-04-15 | 2021-07-14 | Novira Therapeutics Inc. | Combinaisons et procédés comprenant un inhibiteur d'assemblage de capside |
WO2017182493A1 (fr) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Dérivés d'indazole destinés à être utilisés dans la régulation négative du récepteur d'œstrogène pour le traitement du cancer |
CA3022377A1 (fr) * | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Mesure ciblee de l'activite transcriptionnelle liee aux recepteurs hormonaux |
WO2017197904A2 (fr) * | 2016-05-08 | 2017-11-23 | 上海诚妙医药科技有限公司 | Nouvelles formes cristallines de palbociclib, procédé de préparation et utilisation associés |
WO2017197036A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères spirocycliques pour la dégradation de protéines cibles |
EP3455218A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles |
WO2017197055A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
CN109843882A (zh) | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
WO2017216279A1 (fr) * | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | Modulateurs des récepteurs des œstrogènes hétéroaryles et leurs utilisations |
CN109415361B (zh) * | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
EA201990187A1 (ru) | 2016-07-01 | 2019-07-31 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
JP7050770B2 (ja) * | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
WO2018081168A2 (fr) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène |
CN109843888B (zh) | 2016-10-24 | 2022-03-01 | 阿斯利康(瑞典)有限公司 | 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物 |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
WO2018130124A1 (fr) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | Composé tricyclique utilisé en tant que régulateur sélectif du récepteur des œstrogènes et son utilisation |
WO2018130123A1 (fr) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | Composé pentacyclique utilisé en tant que régulateur sélectif du récepteur des œstrogènes et son utilisation |
PE20191500A1 (es) * | 2017-01-30 | 2019-10-22 | Astrazeneca Ab | Moduladores del receptor de estrogeno |
EP4119552A1 (fr) | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Régulation de récepteurs d'antigène chimériques |
AU2018217809A1 (en) | 2017-02-10 | 2019-08-22 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
CN108864080B (zh) * | 2017-05-09 | 2021-10-15 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的四环类化合物及其应用 |
WO2018233591A1 (fr) * | 2017-06-20 | 2018-12-27 | 江苏恒瑞医药股份有限公司 | Sel de dérivé de benzopipéridine et forme cristalline de celui-ci, procédé de préparation du sel et de la forme cristalline de celui-ci |
AU2018291026B2 (en) | 2017-06-29 | 2022-09-01 | G1 Therapeutics, Inc. | Morphic forms of GIT38 and methods of manufacture thereof |
JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
EA038160B1 (ru) * | 2017-11-30 | 2021-07-15 | Астразенека Аб | Модуляторы рецептора эстрогена |
CN109867659A (zh) * | 2017-12-04 | 2019-06-11 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物的制备方法 |
US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
CN112041294B (zh) * | 2018-02-23 | 2024-02-20 | 晶体工程智能研究中心 | 泛醇的共晶和包含所述共晶的组合物 |
EA202092171A1 (ru) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Схема дозирования модулятора сборки капсида |
TW202016084A (zh) * | 2018-05-30 | 2020-05-01 | 大陸商迪哲(江蘇)醫藥有限公司 | 選擇性雌激素受體下調劑和其用途 |
KR102682985B1 (ko) | 2018-06-21 | 2024-07-10 | 에프. 호프만-라 로슈 아게 | 3-((1R,3R)-1-(2,6-다이플루오로-4-((1-(3-플루오로프로필)아제티딘-3-일)아미노)페닐)-3-메틸-1,3,4,9-테트라하이드로-2H-피리도[3,4-b]인돌-2-일)-2,2-다이플루오로프로판-1-올의 고체 형태, 치환된 페닐 또는 피리딘일 잔기를 포함하는 융합된 삼환형 화합물의 제조 방법, 및 이의 사용 방법 |
AU2019299221A1 (en) | 2018-07-03 | 2021-02-04 | The Board Of Trustees Of The University Of Illinois | Activators of the unfolded protein response |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
JP7448541B2 (ja) * | 2018-12-24 | 2024-03-12 | インベンティスバイオ カンパニー リミテッド | 選択的エストロゲン受容体分解剤の新規な塩 |
CN113454077A (zh) | 2019-02-22 | 2021-09-28 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
KR20220005549A (ko) | 2019-05-06 | 2022-01-13 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유도성 질환의 치료에 유용한 아미드 유도체 |
CN113811333B (zh) * | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
US11278532B2 (en) | 2019-08-06 | 2022-03-22 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
CN114945570A (zh) * | 2019-11-04 | 2022-08-26 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂的盐和形式 |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
JP2023509375A (ja) | 2019-12-20 | 2023-03-08 | シーフォー セラピューティクス, インコーポレイテッド | Egfrの分解のためのイソインドリノン及びインダゾール化合物 |
TW202140495A (zh) | 2020-01-10 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 三環四氫異喹啉類衍生物、其製備方法及其在醫藥上的應用 |
WO2021253380A1 (fr) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Formulations orales et leurs utilisations |
EP4192439A1 (fr) * | 2020-08-05 | 2023-06-14 | Aizant Drug Research Solutions Private Limited | Formes posologiques solides de palbociclib |
JP2023551192A (ja) | 2020-11-23 | 2023-12-07 | サノフイ | 乳がんにおける内分泌療法のモニタリングに使用するためのer制御遺伝子のパネル |
JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CA3226156A1 (fr) * | 2021-07-08 | 2023-01-12 | Olema Pharmaceuticals, Inc. | Methodes de traitement de maladies associees au recepteur des oestrogenes_______________________________________________________________ |
MX2024000486A (es) | 2021-07-09 | 2024-01-30 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Tipos de sal de derivado de tetrahidroisoquinolina triciclico. |
WO2023221123A1 (fr) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Formes cristallines d'un antagoniste du récepteur des oestrogènes |
WO2024030968A1 (fr) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Composés pour moduler la protéine ret |
WO2024097989A1 (fr) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Agents de dégradation de protéine ret-ldd |
WO2024097980A1 (fr) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Inhibiteurs de protéines ret-ldd |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO1997039748A1 (fr) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulateurs de molecules possedant des unites de reconnaissance de la phosphotyrosine |
FR2778404B1 (fr) * | 1998-05-06 | 2000-06-30 | Hoechst Marion Roussel Inc | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
ES2287016T3 (es) | 1999-04-28 | 2007-12-16 | Sanofi-Aventis Deutschland Gmbh | Derivados de diaril-acido como ligandos del receptor ppar. |
FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
HUP0300894A3 (en) * | 2000-03-15 | 2008-05-28 | Sanofi Aventis Deutschland | Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use |
US6720331B2 (en) | 2001-04-03 | 2004-04-13 | National Sun Yat-Sen University | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents |
AU2003205630A1 (en) | 2002-01-18 | 2003-07-30 | The Genetics Company Inc. | Beta-secretase inhibitors |
DE60322869D1 (de) | 2002-04-22 | 2008-09-25 | Univ Johns Hopkins | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
JP4671123B2 (ja) | 2003-06-23 | 2011-04-13 | 小野薬品工業株式会社 | 新規三環性複素環化合物 |
AU2004261627C1 (en) * | 2003-07-28 | 2009-02-05 | Smithkline Beecham Corporation | Cycloalkylidene compounds as modulators of estrogen receptor |
DE10335725A1 (de) | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate |
EP1706404A2 (fr) * | 2004-01-23 | 2006-10-04 | Chiron Corporation | Composes de tetrahydrocarboline comme agents anticancereux |
DE602005006539D1 (de) * | 2004-03-11 | 2008-06-19 | Actelion Pharmaceuticals Ltd | Tetrahydropyridoindolderivate |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
US20060094747A1 (en) | 2004-10-28 | 2006-05-04 | The Institute For Pharmaceutical Discovery, L.L.C. | Substituted carboxylic acids |
JP2008520683A (ja) | 2004-11-18 | 2008-06-19 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | タンパク質チロシンホスファターゼ阻害剤としてのヘテロシクリルビフェニル誘導体 |
AU2006214319A1 (en) | 2005-02-14 | 2006-08-24 | Miikana Therapeutics, Inc. | Fused heterocyclic compounds useful as inhibitors of histone deacetylase |
EP1863810A4 (fr) * | 2005-03-22 | 2010-03-31 | Astrazeneca Ab | NOUVEAUX DERIVES DE TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE UTILISES COMME LIGANDS DU RECEPTEUR CB1' |
US20070032385A1 (en) | 2005-06-20 | 2007-02-08 | Dunetz Joshua R | Sustainable chemical processes |
CA2652235A1 (fr) | 2006-05-09 | 2007-11-22 | Hemaquest Pharmaceuticals, Inc. | Procedes de traitement de troubles sanguins |
LT2057156T (lt) | 2006-08-23 | 2017-05-25 | Kudos Pharmaceuticals Limited | 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai |
CA2662218A1 (fr) | 2006-08-29 | 2008-03-06 | Reinnervate Limited | Composes retinoides et leur utilisation |
WO2008124838A1 (fr) | 2007-04-10 | 2008-10-16 | University Of Maryland, Baltimore | Composés qui inhibent les ligases de l'adn humain et procédés de traitement du cancer |
US20100249234A1 (en) | 2007-04-10 | 2010-09-30 | Uwm Research Foundation, Inc. | Methods of reducing virulence in bacteria |
US20100158858A1 (en) | 2007-04-13 | 2010-06-24 | Liangxian Cao | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
JP2010533712A (ja) | 2007-07-19 | 2010-10-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物としてのベータカルボリン誘導体 |
US8198292B2 (en) | 2008-07-03 | 2012-06-12 | Osteogenex, Inc. | Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof |
TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
WO2010107485A1 (fr) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Inhibiteurs de ligase e3 |
WO2010138706A1 (fr) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Procédés de traitement d'un cancer du sein |
US9351964B2 (en) * | 2009-05-27 | 2016-05-31 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
WO2013022740A2 (fr) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Ligands de gpr35 et leurs utilisations |
-
2014
- 2014-05-27 PL PL14727036T patent/PL3004090T3/pl unknown
- 2014-05-27 CN CN201480028785.1A patent/CN105229004B/zh not_active Expired - Fee Related
- 2014-05-27 MX MX2015016428A patent/MX361538B/es active IP Right Grant
- 2014-05-27 SI SI201430531T patent/SI3004090T1/en unknown
- 2014-05-27 DK DK14727036.7T patent/DK3004090T3/en active
- 2014-05-27 CA CA2911859A patent/CA2911859A1/fr not_active Abandoned
- 2014-05-27 ES ES14727036.7T patent/ES2654161T3/es active Active
- 2014-05-27 WO PCT/GB2014/051607 patent/WO2014191726A1/fr active Application Filing
- 2014-05-27 AU AU2014272856A patent/AU2014272856B2/en not_active Ceased
- 2014-05-27 PE PE2015002429A patent/PE20160874A1/es active IP Right Grant
- 2014-05-27 PT PT147270367T patent/PT3004090T/pt unknown
- 2014-05-27 US US14/287,332 patent/US9155727B2/en not_active Expired - Fee Related
- 2014-05-27 UY UY0001035590A patent/UY35590A/es not_active Application Discontinuation
- 2014-05-27 LT LTEP14727036.7T patent/LT3004090T/lt unknown
- 2014-05-27 EP EP14727036.7A patent/EP3004090B1/fr active Active
- 2014-05-27 JP JP2016516235A patent/JP6286031B2/ja not_active Expired - Fee Related
- 2014-05-27 AP AP2015008858A patent/AP2015008858A0/xx unknown
- 2014-05-27 ME MEP-2017-292A patent/ME02892B/fr unknown
- 2014-05-27 SG SG11201509393VA patent/SG11201509393VA/en unknown
- 2014-05-27 TW TW103118498A patent/TWI653235B/zh not_active IP Right Cessation
- 2014-05-27 HU HUE14727036A patent/HUE035738T2/en unknown
- 2014-05-27 RS RS20171304A patent/RS56678B1/sr unknown
- 2014-05-27 KR KR1020157036820A patent/KR20160013198A/ko not_active Application Discontinuation
- 2014-05-27 EP EP17196495.0A patent/EP3360875A1/fr not_active Withdrawn
- 2014-05-27 TN TN2015000516A patent/TN2015000516A1/en unknown
- 2014-05-27 RU RU2015151502A patent/RU2664109C2/ru active
- 2014-05-27 BR BR112015029455A patent/BR112015029455A8/pt not_active Application Discontinuation
-
2015
- 2015-08-31 US US14/840,342 patent/US9616050B2/en active Active
- 2015-11-11 DO DO2015000274A patent/DOP2015000274A/es unknown
- 2015-11-12 IL IL242559A patent/IL242559B/en not_active IP Right Cessation
- 2015-11-24 PH PH12015502615A patent/PH12015502615B1/en unknown
- 2015-11-27 NI NI201500167A patent/NI201500167A/es unknown
- 2015-11-27 CL CL2015003491A patent/CL2015003491A1/es unknown
- 2015-11-30 CR CR20150629A patent/CR20150629A/es unknown
-
2016
- 2016-09-22 HK HK16111116.8A patent/HK1222859A1/zh not_active IP Right Cessation
-
2017
- 2017-02-28 US US15/445,000 patent/US10130617B2/en not_active Expired - Fee Related
- 2017-12-18 HR HRP20171961TT patent/HRP20171961T1/hr unknown
-
2018
- 2018-01-03 CY CY20181100009T patent/CY1120474T1/el unknown
- 2018-10-12 US US16/158,527 patent/US20190038607A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1222859A1 (zh) | 化合物 | |
HRP20180839T1 (hr) | Kemijske vrste | |
AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
GB201304245D0 (en) | Chemical compounds | |
GB201309085D0 (en) | Compounds | |
GB201302927D0 (en) | Compounds | |
GB201310542D0 (en) | Compounds | |
HK1214592A1 (zh) | 化合物 | |
GB201309508D0 (en) | Compounds | |
AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
EP3010923A4 (fr) | Composés de pyrroloquinazoline | |
EP2948457A4 (fr) | Composés | |
GB201306794D0 (en) | Compounds | |
GB201322733D0 (en) | Chemical compounds | |
GB201310460D0 (en) | Compounds | |
GB201313885D0 (en) | Chemical Compounds | |
GB201306881D0 (en) | Chemical compounds | |
GB201310464D0 (en) | Compounds | |
GB201310115D0 (en) | Compounds | |
GB201310047D0 (en) | Compounds | |
GB201309728D0 (en) | Compounds | |
GB201309015D0 (en) | Compounds | |
GB201308975D0 (en) | Compounds | |
GB201308409D0 (en) | Compounds | |
GB201307938D0 (en) | Compounds |